Manetta A, Satyaswaroop P G, Hamilton T, Ozols R, Mortel R
Department of Obstetrics and Gynecology, University of California Irvine Medical Center, University of California, Orange 92668.
Gynecol Oncol. 1989 Mar;32(3):368-70. doi: 10.1016/0090-8258(89)90643-4.
The therapeutic value of 131I-OC125, a radiolabeled monoclonal antibody directed against a human ovarian tumor associated antigen CA125, was examined in an ascites forming intraperitoneal human ovarian carcinoma nude mouse model. Nude mice were injected intraperitoneally with NIH:OVCAR3 cells. Twenty-one days after tumor transplantation, groups of animals were injected intraperitoneally as follows: Group 1 with 200 microCi of 131I-OC125 (n = 20), Group 2 with 200 microCi of 131I (n = 17), Group 3 with 200 microCi of 131I-IgG (n = 21), Group 4 with 60 micrograms of OC125 (n = 18), and Group 5 was left untreated (n = 21). Survival of the tumor-bearing animals was used as the endpoint of the experiment. Mean survivals were found to be 52 +/- 18 days for the 131I-OC125 group, 53 +/- 16 days for the 131I-IgG group, 49 +/- 13 days for the 131I group, 47 +/- 24 days for the OC125 group, and 47 +/- 15 days for the untreated control. These results would indicate no therapeutic advantage of 131I-OC125 over controls in this animal model. However, other approaches using single as well as multiple radiolabeled monoclonal antibodies need to be tested in this model in order to definitely establish the efficacy of this treatment modality.
在一种可形成腹水的人卵巢癌裸鼠模型中，研究了针对人卵巢肿瘤相关抗原CA125的放射性标记单克隆抗体131I-OC125的治疗价值。将NIH:OVCAR3细胞腹腔注射到裸鼠体内。肿瘤移植21天后，将动物分组并进行如下腹腔注射：第1组注射200微居里的131I-OC125（n = 20），第2组注射200微居里的131I（n = 17），第3组注射200微居里的131I-IgG（n = 21），第4组注射60微克的OC125（n = 18），第5组不进行治疗（n = 21）。以荷瘤动物的存活情况作为实验终点。结果发现，131I-OC125组的平均存活时间为52±18天，131I-IgG组为53±16天，131I组为49±13天，OC125组为47±24天，未治疗对照组为47±15天。这些结果表明，在该动物模型中，131I-OC125相对于对照组没有治疗优势。然而，为了明确确定这种治疗方式的疗效，需要在该模型中测试使用单标记和多标记单克隆抗体的其他方法。
